CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT04633278 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: CMP-001
DRUG: Pembrolizumab

Sponsor

Regeneron Pharmaceuticals